SanBio Company Limited (4592) Cash flow
Market cap
¥159.8B
P/E ratio
-28.4x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
| 2015/01 | 2016/01 | 2017/01 | 2018/01 | 2019/01 | 2020/01 | 2021/01 | 2022/01 | 2023/01 | 2024/01 | 2025/01 | 2026/01 | |
| Depreciation & amortization | 6 | 14 | 27 | 54 | 37 | 40 | 74 | 132 | 25 | 15 | 9 | 8 |
| Cash from operations | -219 | -1,362 | -1,796 | -1,907 | -3,968 | -5,717 | -5,216 | -6,547 | -7,434 | -4,766 | -3,603 | -3,761 |
| Capital expenditures | -3 | -60 | -97 | -32 | -6 | -96 | -96 | -42 | -8 | -11 | -5 | -33 |
| Cash from investing | -480 | -436 | 79 | 658 | -1,007 | -115 | 4,180 | -66 | -10 | -19 | -4 | -231 |
| Proceeds from issuance of term debt, net | 1,100 | - | 900 | 1,650 | 1,800 | 500 | 2,300 | - | - | - | - | - |
| Repayments of term debt | - | - | -800 | -550 | -67 | -533 | -2,800 | -975 | -1,592 | -268 | -268 | -268 |
| Cash from financing | 1,374 | 7,402 | 159 | 982 | 12,720 | 7,022 | -57 | -1,495 | 9,446 | 2,371 | 2,091 | 15,963 |